Trials / Withdrawn
WithdrawnNCT05531708
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
Safety and Efficacy Study of Novel Mesothelin CAR-T Cell Therapy in Patients With Mesothelin-positive Advanced Refractory Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Shanghai Pudong Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of novel Mesothelin CAR-T in patients with Mesothelin-positive advanced refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Anti-mesothelin CAR-T cells | D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously. |
| DRUG | Fludarabine | D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days. |
| DRUG | Cyclophosphamide | D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days. |
Timeline
- Start date
- 2021-04-02
- Primary completion
- 2025-04-30
- Completion
- 2026-04-30
- First posted
- 2022-09-08
- Last updated
- 2023-03-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05531708. Inclusion in this directory is not an endorsement.